PwC Report Warns Drugmakers of Potential Tax Pitfalls of Personalized Medicine

A changing R&D paradigm fueled by the growing demand for personalized medicine is "one of the reasons that the pharmaceutical industry is facing rising taxes," a PricewaterhouseCoopers expert said. As a result, a PwC report released earlier this month advised pharma, biotech, and device firms to invest in tax planning early in their business strategic decisions.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.